Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.57 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767339 | 0.83 | RAB9A (0.51) | HPGDSKMT2ASMN1; SMN2 | |
| SCHEMBL13213725 | 0.82 | POLB (0.50) | PTGS1HPGDSKMT2ASMN1; SMN2 | |
| SCHEMBL396727 | 0.81 | POLB (0.53) | HPGDSKMT2A | |
| SCHEMBL14699724 | 0.81 | KMT2A (0.54) | HPGDSKMT2ASMN1; SMN2 | |
| SCHEMBL14937486 | 0.78 | TLR7 (0.51) | OXTRAVPR1AKMT2ASMN1; SMN2 | |
| SCHEMBL28401432 | 0.78 | GRM5 (0.51) | TRPV1PTGS1GRM5KMT2A | |
| SCHEMBL6331796 | 0.78 | HPGDS (0.46) | OXTRAVPR1AHPGDSKMT2ASMN1; SMN2 | |
| SCHEMBL22246762 | 0.78 | GRM5 (0.63) | PTGS1GRM5KMT2A | |
| SCHEMBL8016742 | 0.76 | KMT2A (0.51) | OXTRAVPR1AHPGDSKMT2ASMN1; SMN2 | |
| SCHEMBL4035180 | 0.76 | MAPK14 (0.56) | HPGDSKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642626-B2 | Ethinyl-pyrazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| EP-2604602-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-2599775-A1 | ETHINYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130123500-A1 | ETHINYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | GRIN2C, GRIN2B, GRIN3A | OXTR 114/4885AVPR1A 919/4885TRPV1 88/4885 |
| US-20130123500-A1 | ETHINYL-PYRAZOLE DERIVATIVE | GABRE, GRIN3A, GRIK5 | OXTR 112/4885AVPR1A 679/4885TRPV1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.